Clinical Trial Search

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 7 — 1.512; 1.389; 1.395; 1.286 Liters

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Number of Patients With Response — 0; 2; 14; 15 participants

Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05

Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants

Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…

Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC

Primary: Progression-free Survival — 4 months

Primary: Percentage of Participants With Antibody Titer ≥40 at 28 Days Post Vaccination — 97.5; 97.4; 97.7; 90.0 percentage of participants

Primary: Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia — 7; 4; 0; 9 participants

Primary: Number of Confirmed Responses, Defined to be an sCR, CR, VGPR, or PR Noted as the Objective Status on Two Consecutive Evaluations. — 0; 0; 0; 0 participants

Primary: Percent Change in LDL-C After 8 Weeks of Therapy — -39.6; -49.9 Percent Change

Primary: LDL-C — -50.94 percentage change in LDL-C

Primary: Absolute Change From Baseline in Percent Hepatic Fat — 0.03; 4.72 Percent of Hepatic Fat — p=<0.001